Dofetilide
- Generic Name
- Dofetilide
- Brand Names
- Tikosyn
- Drug Type
- Small Molecule
- Chemical Formula
- C19H27N3O5S2
- CAS Number
- 115256-11-6
- Unique Ingredient Identifier
- R4Z9X1N2ND
- Background
Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter.
- Indication
用于心房扑动、心房颤动、室上性心动过速。
- Associated Conditions
- Normal Sinus Rhythm, Symptomatic Atrial flutter, Symptomatic, recurrent Atrial Fibrillation
- Associated Therapies
- -
Improvement in Endothelial Dysfunction After Initiation of Anti-arrhythmic Therapy in Atrial Fibrillation Patients
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Samir Saba
- Target Recruit Count
- 12
- Registration Number
- NCT04128878
- Locations
- 🇺🇸
University of Pittsburgh Medical Center - Presbyterian University Hospital, Pittsburgh, Pennsylvania, United States
Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2015-05-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT02365532
- Locations
- 🇺🇸
Spaulding Clinical Research, LLC, West Bend, Wisconsin, United States
Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block
- Conditions
- Interventions
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2016-06-08
- Lead Sponsor
- Food and Drug Administration (FDA)
- Target Recruit Count
- 22
- Registration Number
- NCT02308748
Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2013-06-10
- Last Posted Date
- 2018-03-08
- Lead Sponsor
- Food and Drug Administration (FDA)
- Target Recruit Count
- 22
- Registration Number
- NCT01873950
High Intensity Focused Ultrasound (HIFU) Ablation System Study
- Conditions
- Interventions
- First Posted Date
- 2006-10-25
- Last Posted Date
- 2008-06-17
- Lead Sponsor
- ProRhythm, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT00392106
- Locations
- 🇺🇸
Piedmont Hospital, Atlanta, Georgia, United States
🇺🇸Lahey Clinic, Burlington, Massachusetts, United States
🇺🇸Stony Brook University Hospital, Stony Brook, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.